Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06298630 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Follow-up Study of BRL-101 for TDT

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 7 of 7 sites
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bioray Laboratories
10 trials monitored
See 1 trial at risk
Thalassemia
161 trials monitored
See 6 trials at risk
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Trial Details
NCT Number NCT06298630
Lead Sponsor Bioray Laboratories
Collaborators: First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Shenzhen Children's Hospital
Conditions
(from sponsor)		 Thalassemia, Beta
Related terms beta-Thalassemia
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov